Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Benzamides
  • Gastrointestinal Neoplasms
  • Gastrointestinal Stromal Tumors
  • Piperazines
  • Pyrimidines

abstract

  • Adjuvant imatinib in patients with primary GIST who are at high risk of recurrence prolongs OS compared with that of historical controls. Optimal duration of adjuvant therapy remains undefined. (NCT00025246).

publication date

  • September 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4041735

Digital Object Identifier (DOI)

  • 10.1097/SLA.0b013e3182a15eb7

PubMed ID

  • 23860199

Additional Document Info

start page

  • 422

end page

  • 9

volume

  • 258

number

  • 3